Inhalation Sciences Sweden AB is a Contract Research Organization Supporting Enhanced Preclinical and Clinical Research in Early Drug Development.
The company is developing a new patented development path for inhalation drugs and inhaler devices that will lead to efficient aerosol therapies.
The business concept is based on creating early predictive preclinical and clinical pharmacokinetics while staying in control of dosing and mass balance throughout the development process, using only minute amounts of a compound.
The development path extends from discovery to early clinical trials.
It is envisaged that this new process of precision dosing will reduce late stage product attritions and significantly cut costs, timelines, and improve the productivity in respiratory drug development.